<DOC>
	<DOCNO>NCT00712803</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study evaluate safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN3-3'Ddelta30 ) Healthy Adults</brief_title>
	<detailed_description>Dengue virus cause dengue fever severe dengue hemorrhagic fever/shock syndrome . More 2 billion people live tropical subtropical region world risk dengue virus infection , lead cause hospitalization death child several tropical Asian country . This study evaluate safety immunogenicity live attenuate dengue virus vaccine call rDEN3-3'D4delta30 . This vaccine derive rDEN4delta30 , another dengue virus vaccine candidate show safe immunogenic Phase I II trial healthy adult . There two group study . Participants Group 1 randomly assign receive rDEN3-3'D4delta30 vaccine placebo study entry . The dose Group 2 determine safety review participant Group 1 . If less 90 % Group 1 participant seroconvert DEN3 participant Group 2 receive high dose rDEN3-3'D4delta30 . If least 90 % Group 1 participant seroconvert DEN3 , participant Group 2 receive low dose rDEN3-3'D4delta30 . All participant require monitor temperature three time day first 16 day follow vaccination . Study visit occur 30 minute follow vaccination every day vaccination Day 16 , follow four additional visit select day Day 180 . Blood collection , vital sign measurement , target physical exam occur study visit . Some participant ask undergo skin biopsy additional blood collection select visit .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>General good health Available duration study Willing use accept form contraception Clinically significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease history , physical examination , laboratory study include urinalysis Behavioral , cognitive , psychiatric disease , opinion investigator , may interfere study Certain abnormal laboratory value . More information criterion find protocol . Medical , work , family problem result alcohol illegal drug use within 12 month study entry History severe allergy anaphylaxis Severe asthma require emergency room visit hospitalization within 6 month study entry HIV infect Hepatitis C virus infect Hepatitis B surface antibody positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive drug 30 day prior study entry . Participants use topical nasal corticosteroid exclude . Receipt live vaccine within 4 week study entry Receipt kill vaccine within 2 week study entry Absence spleen Plan travel area dengue virus common Any investigational product within 30 day study entry Other condition , opinion investigator , would interfere study Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>